Likelihood of Approval and Phase Transition Success Rate Model – Sacituzumab Tirumotecan in Cervical Cancer
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Sacituzumab Tirumotecan in Cervical Cancer report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Sacituzumab Tirumotecan in Cervical Cancer Drug Details:
Sacituzumab Tirumotecan (Giatelai) is a conjugated humanized monoclonal antibody with potential antineoplastic activity. It is formulated as lyophilized powder for solution for intravenous route of administration. Giatelai is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have previously received at least two systemic treatments (at least one of which was for the advanced or metastatic stage).sacituzumab tirumotecan (SKB-264) is under development for the treatment of ovarian epithelial cancer, gastric adenocarcinoma, triple negative breast cancer, endometrial carcinoma, HER2 negative breast cancer, HER2-negative gastroesophageal junction adenocarcinoma, metastatic pancreatic ductal adenocarcinoma, colorectal cancer, bile duct cancer, head and neck cancer squamous cell carcinoma, oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, adenocarcinoma of the gastroesophageal junction, squamous and non-squamous non-small cell lung cancer, small cell lung cancer, nasopharyngeal carcinoma, metastatic cervical cancer, metastatic castration-resistant prostate cancer, fallopian tube cancer, peritoneal cancer, esophageal squamous cell carcinoma, non-muscle invasive bladder cancer, urothelial cancers including renal cancer, ureter cancer and urethral cancer. It is a third-generation antibody-drug conjugate that acts by targeting cells expressing (trophoblast antigen) TROP2. It is administered through intravenous and intravesical route in the form of powder. The drug candidate is being developed based on the ADC conjugation technology.It was under development for the treatment of pancreatic ductal adenocarcinoma, colorectal cancer and bladder cancer.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Sacituzumab Tirumotecan LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports